Stockscreener 앱 받기
21.00
0.80%
-0.17
전일 마감가:
$21.17
열려 있는:
$21.25
하루 거래량:
267.35K
Relative Volume:
0.78
시가총액:
$736.97M
수익:
-
순이익/손실:
$-74.31M
주가수익비율:
-8.4619
EPS:
-2.4817
순현금흐름:
$-62.86M
1주 성능:
-0.71%
1개월 성능:
-8.62%
6개월 성능:
+22.81%
1년 성능:
+809.09%
1일 변동 폭
$20.67
$22.12
1주일 범위
$19.39
$22.79
52주 변동 폭
$2.15
$28.44
Alto Neuroscience Inc Stock (ANRO) Company Profile
명칭
Alto Neuroscience Inc
전화
773-255-5012
주소
650 CASTRO STREET, SUITE 450, MOUNTAIN VIEW
Compare ANRO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ANRO
Alto Neuroscience Inc
|
21.00 | 742.94M | 0 | -74.31M | -62.86M | -2.4817 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Alto Neuroscience Inc Stock (ANRO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 재개 | Chardan Capital Markets | Buy |
| 2025-11-17 | 개시 | BTIG Research | Buy |
| 2025-09-29 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-23 | 다운그레이드 | Rodman & Renshaw | Buy → Neutral |
| 2024-10-23 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2024-09-03 | 개시 | Wedbush | Outperform |
| 2024-02-27 | 개시 | Jefferies | Buy |
| 2024-02-27 | 개시 | Robert W. Baird | Outperform |
| 2024-02-27 | 개시 | Stifel | Buy |
| 2024-02-27 | 개시 | TD Cowen | Outperform |
| 2024-02-27 | 개시 | William Blair | Outperform |
모두보기
Alto Neuroscience Inc 주식(ANRO)의 최신 뉴스
Nature Medicine trial: pramipexole eased 'pleasure loss' in depression - Stock Titan
Alto Neuroscience Inc. (ANRO) Q1 2026 Earnings: Wider-than-Expected Loss as Clinical-Stage Biotech Advances PipelineRevenue Beat Analysis - newsline.com
ANRO Q1 2026 Earnings: Wider-than-Expected Loss Weighs on Investor SentimentEarnings Cycle Outlook - newsline.com
ANRO: Three late-stage psychiatry programs expect pivotal data readouts in 2027 - TradingView
Alto Neuroscience (ANRO) Edges Lower as Stock Hovers Near Key Support ZoneIndex Put Call - The Legal Advocate
Alto Neuroscience (ANRO) director awarded 26,000 stock options at $20.44 strike price - Stock Titan
Alto Neuroscience (ANRO) director Andrew Craig Miller files initial Form 3 - Stock Titan
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller to Board of Directors - geneonline.com
Alto Neuroscience, Inc. (ANRO) Files 8-K Report Announcing No Soliciting Material or Tender Offers – Company Info & NYSE Listing - Minichart
Alto Neuroscience appoints Andrew Miller to board of directors By Investing.com - Investing.com South Africa
Alto Neuroscience appoints Andrew Miller to board of directors - Investing.com
Biotech leader Andrew Miller joins Alto Neuroscience (ANRO) board and governance committee - Stock Titan
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors - Business Wire
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy - Investing.com UK
H.C. Wainwright Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $50 - Moomoo
H.C. Wainwright reiterates Alto Neuroscience stock rating at buy By Investing.com - Investing.com Australia
Wolfe Research initiates Alto Neuroscience stock with outperform rating - Investing.com India
ANRO Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEBITDA Estimate Trend - newsline.com
Alto Neuroscience Analyst Ratings and Price Targets | NYSE:ANRO - Benzinga
BofA Securities Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $33 - Moomoo
BofA Securities Adjusts Price Target on Alto Neuroscience to $33 From $35 - marketscreener.com
Wolfe Research initiates Alto Neuroscience stock with outperform rating By Investing.com - Investing.com Nigeria
symbol__ Stock Quote Price and Forecast - CNN
ANRO Stock Price, Quote & Chart | ALTO NEUROSCIENCE INC (NYSE:ANRO) - ChartMill
Alto Neuroscience: Buy Rating Reiterated as Lead Asset Advances and Cash Runway Extends; $28 Price Target Maintained - TipRanks
Alto Neuroscience Is Maintained at Outperform by Baird - Moomoo
Alto Neuroscience Price Target Cut to $36.00/Share From $38.00 by Baird - Moomoo
Baird Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Cuts Target Price to $36 - Moomoo
Alto Neuroscience (ANRO) CEO gifts 400,000 shares to family trust - Stock Titan
Alto Neuroscience (ANRO) Vestal Point reports 6.5% ownership - Stock Titan
Point72 affiliates, Steven A. Cohen hold 3.7% of Alto Neuroscience (ANRO) - Stock Titan
[SCHEDULE 13G/A] Alto Neuroscience, Inc. Amended Passive Investment Disclosure - Stock Titan
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO) and Radnet (RDNT) - The Globe and Mail
JonesTrading Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
Mental health scientist wins Columbia Transformational Research Award - Stock Titan
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - Business Wire
Sirenia, Alex Silverstein disclose 7.9% stake in Alto Neuroscience (ANRO) - Stock Titan
Jefferies Maintains Alto Neuroscience(ANRO.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Alto Neuroscience (NASDAQ: ANRO) director receives 10,958 stock option grant - Stock Titan
Alto Neuroscience (ANRO) director gets 10,958 options at $24.63 strike - Stock Titan
Alto Neuroscience (ANRO) director receives 10,958-share stock option grant - Stock Titan
Alto Neuroscience (ANRO) director awarded 10,958 stock options as compensation - Stock Titan
York Gwill receives 10,958 Alto Neuroscience (ANRO) stock options grant - Stock Titan
A Quick Look at Today's Ratings for Alto Neuroscience(ANRO.US), With a Forecast Between $24 to $28 - Moomoo
Alto Neuroscience, Inc. Reports Q1 2026 Financial Results and Provides Business Update - Minichart
ANRO: ALTO-207 demonstrates robust efficacy in TRD, with late-stage trials and major catalysts ahead - TradingView
Alto Neuroscience: Runway To Fund Planned Operations Through 2029 >ANRO - Moomoo
Alto Neuroscience Shareholders Shape Governance and Equity Plans - TipRanks
Alto Neuroscience (ANRO) OKs ESPP amendment but rejects equity plan change - Stock Titan
Alto Neuroscience, Inc. Stock 12‑Month Price Target Raised to $35.52, Implies 44% Upside - TradingView
Alto Neuroscience, Immunovant and other big stocks moving lower in Thursday's pre-market session - MSN
Alto Neuroscience Inc (ANRO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):